Astellas sells DPP-4 patent estate to Royalty Pharma

Astellas Pharma Inc. (Tokyo:4503) sold its dipeptidyl peptidase-4 (DPP-4) patent estate and royalty stream to Royalty Pharma (New York, N.Y.) for $609 million. The IP covering the use of DPP-4 inhibit...